Stevens-Johnson syndrome after treatment with STI571: A case report

Liang Tsai Hsiao; Hung Ming Chung; Jen Tsun Lin; Tzeon Jye Chiou; Jin Hwang Liu; Frank S. Fan; Wei Shu Wang; Chueh Chuan Yen; Po Min Chen

doi:10.1046/j.1365-2141.2002.03499.x

Stevens-Johnson syndrome after treatment with STI571: A case report

Liang Tsai Hsiao, Hung Ming Chung, Jen Tsun Lin, Tzeon Jye Chiou, Jin Hwang Liu, Frank S. Fan, Wei Shu Wang, Chueh Chuan Yen, Po Min Chen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

110 Scopus citations

Abstract

Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life- threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.

Original language	English
Pages (from-to)	620-622
Number of pages	3
Journal	British Journal of Haematology
Volume	117
Issue number	3
DOIs	https://doi.org/10.1046/j.1365-2141.2002.03499.x
State	Published - 2002

Keywords

Chronic myeloid leukaemia
Skin
Stevens-Johnson syndrome
STI571
Tyrosine kinase inhibitor

Access to Document

10.1046/j.1365-2141.2002.03499.x

Cite this

@article{58c720f41489454b8495e2c0cd13d3a6,

title = "Stevens-Johnson syndrome after treatment with STI571: A case report",

abstract = "Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life- threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.",

keywords = "Chronic myeloid leukaemia, Skin, Stevens-Johnson syndrome, STI571, Tyrosine kinase inhibitor",

author = "Hsiao, {Liang Tsai} and Chung, {Hung Ming} and Lin, {Jen Tsun} and Chiou, {Tzeon Jye} and Liu, {Jin Hwang} and Fan, {Frank S.} and Wang, {Wei Shu} and Yen, {Chueh Chuan} and Chen, {Po Min}",

year = "2002",

doi = "10.1046/j.1365-2141.2002.03499.x",

language = "English",

volume = "117",

pages = "620--622",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

TY - JOUR

T1 - Stevens-Johnson syndrome after treatment with STI571

T2 - A case report

AU - Hsiao, Liang Tsai

AU - Chung, Hung Ming

AU - Lin, Jen Tsun

AU - Chiou, Tzeon Jye

AU - Liu, Jin Hwang

AU - Fan, Frank S.

AU - Wang, Wei Shu

AU - Yen, Chueh Chuan

AU - Chen, Po Min

PY - 2002

Y1 - 2002

N2 - Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life- threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.

AB - Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life- threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.

KW - Chronic myeloid leukaemia

KW - Skin

KW - Stevens-Johnson syndrome

KW - STI571

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0036110317&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2002.03499.x

DO - 10.1046/j.1365-2141.2002.03499.x

M3 - Article

C2 - 12028031

AN - SCOPUS:0036110317

SN - 0007-1048

VL - 117

SP - 620

EP - 622

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Stevens-Johnson syndrome after treatment with STI571: A case report

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this